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Background: The heart derives energy from a wide variety of substrates including fatty acids, carbohydrates,
ketones, and amino acids. The healthy heart generates up to 30% of its ATP from glucose. Under conditions of
cardiac injury or stress, the heart relies even more heavily on glucose as a source of fuel. Glucose is transported into
the heart by members of the family of facilitative glucose transporters (GLUTs). While research examining the
transport of glucose into the heart has primarily focused on the roles of the classical glucose transporters GLUT1
and GLUT4, little is known about the functions of more newly identified GLUT isoforms in the myocardium.
Methods: In this study the presence and relative RNA message abundance of each of the known GLUT isoforms
was determined in left ventricular tissue from two commonly used inbred laboratory mouse strains (C57BL/6J and
FVB/NJ) by quantitative real time PCR. Relative message abundance was also determined in GLUT4 null mice and in
murine models of dilated and hypertrophic cardiomyopathy.
Results: GLUT4, GLUT1, and GLUT8 were found to be the most abundant GLUT transcripts in the normal heart,
while GLUT3, GLUT10, and GLUT12 are present at relatively lower levels. Assessment of relative GLUT expression in
left ventricular myocardium from mice with dilated cardiomyopathy revealed increased expression of GLUT1 with
reduced levels of GLUT4, GLUT8, and GLUT12. Compensatory increase in the expression of GLUT12 was observed in
genetically altered mice lacking GLUT4.
Conclusions: Glucose transporter expression varies significantly among murine models of cardiac dysfunction and
involves several of the class III GLUT isoforms. Understanding how these more newly identified GLUT isoforms
contribute to regulating myocardial glucose transport will enhance our comprehension of the normal physiology
and pathophysiology of the heart.
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The mammalian heart demands a constant supply of ATP
in order to perform its vital role in delivering oxygen,
metabolic substrates, and hormones to peripheral tissues.
In order to generate an adequate supply of ATP to meet
this high energy demand, the heart requires a continuous
supply of metabolic fuel. The healthy heart derives its en-
ergy from a wide variety of carbon based substrates* Correspondence: hruz_p@kids.wustl.edu
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distribution, and reproduction in any mediumincluding fatty acids, carbohydrates, ketones, and amino
acids [1]. The flexibility that the healthy heart displays in
its metabolic machinery enables it to alter substrate use
depending on substrate availability and circulating hor-
mone levels. While the healthy heart derives a majority of
its energy from fatty acids, up to 30% of myocardial ATP
is derived from glucose and lactate [2]. Furthermore,
under conditions of myocardial injury or stress, such as
during ischemia or during pressure overload hypertrophy,
the heart displays reduced substrate flexibility with an
increased dependence on glucose [3]. The transport of
glucose into the myocardium is mediated by members of
the facilitative glucose transporter (GLUT) family.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ily: the Class I transporters GLUTs-1, -2, -3, -4, and −14,
the Class II transporters GLUTs-5, -7, -9, and −11, and
the Class III transporters GLUTs-6, -8, -10, -12, and
HMIT [4,5]. These GLUT isoforms differ in their sub-
strate specificity, kinetics of transport, and tissue distri-
bution and localization. Many of the Class II and Class
III isoforms in the GLUT family have been discovered
only in recent years, and the specific role that the newly
identified GLUTs play in mediating the transport of
hexoses across the membranes of mammalian cells
remains poorly understood.
The Class I transporters GLUT1 and GLUT4 are the
most extensively studied GLUTs in mammalian tissues.
GLUT4, the canonical insulin-responsive glucose trans-
porter, is the predominant GLUT expressed in the adult
heart [6]. GLUT1 is a major GLUT transporter
expressed in the fetal heart [7]. GLUT1 also increases in
abundance in the adult heart in response to myocardial
injury or stress [8,9]. In addition to GLUTs-1 and −4,
several of the newly identified GLUT transporters, in-
cluding the Class III isoforms GLUTs-8, -10, and −12,
have been detected in cardiac tissue [10-14]. These iso-
forms may represent additional insulin-responsive
GLUTs, as GLUT8 has been identified as an insulin-
responsive GLUT in blastocysts [15] and GLUT12 over-
expression in mice has been shown to improve whole
body insulin-sensitivity [16]. However, the functional
role of these transporters in regulating myocardial glu-
cose uptake remains largely unexplored. In addition, lit-
tle quantitative data in regards to the expression or
function of these GLUTs in the myocardium are avail-
able. To better understand the role for these newly iden-
tified GLUTs in the heart, we set out to identify which
isoforms of the facilitative glucose transporter family are
present in the left ventricle of mice. Furthermore, we
have used real time PCR to determine quantitatively
which GLUTs transcripts are most highly abundant in
the heart. Identifying the GLUT isoforms that are most
highly expressed in the heart under healthy settings, and
determining how the expression levels of these GLUTs
change under pathological circumstances provides novel
insight into the potential functional roles of these newly
identified GLUTs in the normal physiology and patho-
physiology of the heart.
Materials and methods
Animal care
All mouse studies were approved by the Animal Studies
Committee at Washington University School of Medi-
cine and conform to the Guide for the Care and Use of
Laboratory Animals published by the National Institute
of Health. Mice were housed in the animal facility at
Washington University under standard light/dark cyclesand fed standard mouse chow diet and water ad libitum.
Ten-week-old male FVB/NJ mice and C57BL/6J mice
(The Jackson Laboratory) were used for the identifica-
tion and quantification of GLUT transcripts in the left
ventricle myocardium. Six-month-old male GLUT4 null
mice and age matched C57BL/6J controls were used to
identify the relative GLUT transcript levels in the mur-
ine left ventricle following genetic ablation of GLUT4.
Twelve-week-old male TG9 mice and wild type (FVB/
NJ) littermate controls were used to determine the rela-
tive abundance of GLUT transcripts in the left ventricle
in a genetic model of dilated cardiomyopathy. Male
C57BL/6J mice were used in the aortic banding studies
described below in order to examine the relative abun-
dance of GLUTs in the left ventricle during pathophysio-
logical hypertrophy.
Transverse aortic constriction
Ten-week-old C57BL/6J male mice were randomly
assigned to either a sham-operated or a transverse aortic
constriction (TAC) group. TAC was performed as
described previously [17]. Sham-operated mice endured
the same surgical procedure but the aortic constriction
was not placed. After seven days, surviving animals were
sacrificed and the left ventricles were dissected out and
weighed. The left ventricles were then frozen and RNA
was isolated as described below.
RNA isolation and real-time PCR
Total RNA was isolated using the TrizolW Plus RNA
Purification System (Invitrogen, Carlsbad, CA), and one
microgram of RNA was reverse transcribed using the
SuperScriptW III First-Strand Synthesis System for RT-
PCR (Invitrogen, Carlsbad, CA). PCR was performed
using Klentaq1 (DNA Polymerase Technology, St. Louis,
MO) to identify the GLUT RNA transcripts that are
present in the left ventricles of male FVB/NJ and
C57BL/6J mice. Quantitative RT-PCR was performed
using Power SYBRW Green PCR Master Mix (Applied
Biosystems, Foster City, CA). Each reaction was run in
triplicate using the validated primers listed in Table 1.
Quantifications were performed with standard curves
generated using pCR 2.1-TOPO plasmids (Invitrogen,
Carlsbad, CA) that contain each GLUT cDNA amplicon.
To control for the intrinsic variability in the efficiency of
the reverse transcription reactions for the RNA samples
used in this study, the results were normalized to β-Actin
as described previously [18]. Briefly, the cycle threshold
(Ct) values for β-Actin that were obtained from running
individual cDNA samples in triplicate were averaged.
The average β-Actin Ct values for the entire pool of left
ventricle samples was then determined and this value
was used as a baseline with the ΔΔCt method in order
to create a normalization factor for each individual left
Table 1 Murine glucose transporter primers
Forward primer Reverse primer Amplicon(bp)
Glut1 TCAACACGGCCTTCACTG CACGATGCTCAGATAGGACATC 164
Glut2 TGTGCTGCTGGATAAATTCGCCTG AACCATGAACCAAGGGATTGGACC 109
Glut3 TTCTGGTCGGAATGCTCTTC AATGTCCTCGAAAGTCCTGC 143
Glut4 GTAACTTCATTGTCGGCATGG AGCTGAGATCTGGTCAAACG 155
Glut5 GGCTCATCTTCCCCTTCATTC ATGAATGTCCTGCCCTTGG 145
Glut6 TTGGTGCTGTGAGGCT TGGCACAAACTGGACGTA 140
Glut8 TTCATGGCCTTTCTAGTGACC GAGTCCTGCCTTTAGTCTCAG 145
Glut9 TGCTTCCTCGTCTTCGCCACAATA CTCTTGGCAAATGCCTGGCTGATT 113
Glut10 ACCAAAGGACAGTCTTTAGCTG ATCTTCCAAGCAGACGGATG 148
Glut12 GGGTGTCAACCTTCTCATCTC CCAAAGAGCATCCCTTAGTCTC 149
Actin GATTACTGCTCTGGCTCCTAG GACTCATCGTACTCCTGCTTG 147
HPRT CCCCAAAATGGTTAAGGTTGC AACAAAGTCTGGCCTGTATCC 76
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generated using the standard curve described above for
each left ventricle sample were then normalized to the
value obtained using β-Actin as a normalization factor.
Since β-Actin transcript levels can change in heart fail-
ure [19], the relative changes in GLUT expression in
murine models of cardiac hypertrophy compared to
controls animals were determined using the ΔΔCt
method with HPRT serving as an internal control.Western blotting
Left ventricular myocardium was harvested from mice
immediately following euthanasia and was flash frozen
in liquid nitrogen. Lysates were prepared by homogen-
izing the frozen ventricles in lysis buffer containing
1% triton X100, 1 mM sodium vanadate, 50 mM so-
dium fluoride, 10 mM sodium pyrophosphate, and
protease inhibitor cocktail (Sigma, Saint Louis, MO)
in PBS. Lysates were incubated on ice for 30 minutes
and cleared by centrifugation at 1500xg for 10 min-
utes at 4°C. Protein concentration was determined
using the Pierce BCA Protein Assay Kit (Pierce bio-
technology, Rockford, IL). The GLUT8 and GLUT12
antibodies were a kind gift from Dr. Kelle Moley.
Western blot analysis was then performed using
10 μg of total protein per lane. GLUT1, GLUT4, and
GLUT12 antibodies recognizing the COOH-terminus
of the transporters were used at a 1:1000 dilution in
5% milk in TBS-T. A GLUT8 antibody recognizing
the NH2-terminus of the transporter was used at a
1:1000 dilution in 5% milk in TBS-T. Monoclonal
GAPDH (Sigma, Saint Louis, MO) was used as an in-
ternal control for loading variability. Blots were
imaged and relative protein levels were determined
using the Odyssey Infrared Imaging System Version
3.0 (LI-COR Biosciences, Lincoln, NE).Statistical analyses
The data are reported as means ± SEM. Differences be-
tween control and experimental values were determined
by Student’s t test. Statistical significance is set as
P< 0.05.
Results
GLUT expression in left ventricle
To determine the relative expression of glucose trans-
porters in healthy hearts, two inbred strains of mice
that are most commonly used in laboratory investiga-
tion of cardiac function (C57BL/6J and FVB/NJ) were
selected for initial characterization of cardiac GLUT ex-
pression. Analysis of RNA obtained from left ventricle
myocardium of ten-week-old male mice from both
strains identified transcripts encoding GLUT1, GLUT3,
GLUT4, GLUT8, GLUT10, and GLUT12 (Figure 1A
and Additional file 1: Figure S1). A faint band that is
the appropriate size to be GLUT5 was detected in a
few but not all left ventricle cDNA samples in both
C57BL/6J and FVB/NJ mice. We were not, however,
able to subclone the GLUT5 amplicon derived from left
ventricle cDNA into a pCR2.1-TOPO plasmid for use
in the quantitative real time PCR described below, and
therefore for the purposes of this study we consider the
expression of GLUT5 in the murine left ventricle to be
below detectable levels. We were unable to detect
GLUT6 in the left ventricle of C57BL/6J mice. How-
ever, a band for GLUT6 in the left ventricle of FVB/NJ
mice was observed. Transcripts for GLUT2 or GLUT9
in either C57BL/6J or FVB/NJ mice were not detected.
PCRs were also run on cDNA isolated from liver, intes-
tine, and brain (Figure 1B) to confirm the specificity of
the primers for use in amplifying GLUT2 (liver),
GLUT5 (intestine), GLUT6 (brain), and GLUT9 (liver).
The identity of each GLUT amplicon was confirmed by
sequencing.
Figure 1 Detection of GLUT mRNAs in the left ventricle of
C57BL/6J mice. A) PCR was employed to identify each known
murine member of the facilitative glucose transporter family in the
left ventricle of 10-week-old male C57BL/6J mice. GLUTs-1, -3, -4, -8,
-10, and −12 were amplified using cDNA derived from the left
ventricular myocardium. The identity of each GLUT amplicon was
confirmed by sequencing. GLUTs-2, -5, -6, and −9 were not present
in the left ventricle of male C57BL/6J mice. Representative images
are shown (n= 3). B) The specificity of the primers used to amplify
GLUTs-2, -5, -6, and −9 were confirmed using cDNA derived from
the positive control tissues: liver, intestine, and brain. The specificity
of the primers for each GLUT amplicon was confirmed by
sequencing.
Table 2 Glut mRNA quantification in murine left ventricle
(copy number/ng total RNA)
C57BL/6J males (n = 8)
GLUT1 982± 139
GLUT2 NA






GLUT10 73 ± 26
GLUT12 44 ± 5
ACTIN 15998± 2582
NA, Not applicable. Unable to detect transcript levels.
Table 3 Glut mRNA quantification in murine left ventricle
(copy number/ng total RNA)
FVB/NJ males (n = 8)
GLUT1 457 ± 75
GLUT2 NA
GLUT3 26 ± 2
GLUT4 3202± 447
GLUT5 NA
GLUT6 8 ± 2
GLUT8 268 ± 34
GLUT9 NA
GLUT10 18 ± 2
GLUT12 170 ± 22
ACTIN 9020± 1212
NA, Not applicable. Unable to detect transcript levels.
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Most of the current research investigating the role of
glucose transporters in the myocardium has focused on
the ‘classical’ Class I glucose transporters GLUT1 and
GLUT4. Other facilitative GLUTs, including the more
recently identified Class III GLUTs-8, -10, and −12, are
also present in the heart. Several of these GLUTs are not
yet well characterized, and it is possible that they also
play a significant role in regulating glucose uptake in the
heart. To understand better the extent to which these fa-
cilitative glucose transporters contribute to cardiac glu-
cose utilization, we quantified the absolute levels of
GLUT mRNA in left ventricles derived from C57BL/6J
and FVB/NJ mice, two of the commonly used strains in
genetic and surgical studies of cardiac hypertrophy.
Tables 2 and 3 display the copy numbers of GLUT
mRNA transcripts per nanogram of total RNA derived
from murine left ventricles. We found that GLUT4, fol-
lowed by GLUT1, is the predominant GLUT expressed
in the murine left ventricle myocardia (Tables 2 and 3).
mRNAs for GLUTs-3, -8, -10, and −12 are present in
the left ventricle, but in considerably lower abundance.
GLUT8 has the next highest mRNA level following
GLUT4 and GLUT1. However, it is still not clearwhether GLUT8 preferentially transports glucose or
other hexoses in vivo, as well as if GLUT8’s primary role
is at the cell surface or in an intracellular compartment,
and thus its role in energy production in the heart is
currently unclear. In FVB/NJ mice, GLUT12 is the
fourth most abundant GLUT transcript in the LV after
GLUT8. GLUT12 is currently hypothesized to act as a
second insulin-responsive GLUT in addition to GLUT4.
The functional role of GLUT12 in facilitating insulin-
responsive glucose transport in this organ, however, has
not been fully elucidated [16,20]. GLUT6 was expressed
at almost undetectable levels in LVs from FVB/NJ mice.
GLUT transcript expression in GLUT4 null myocardium
GLUT4 is the predominant facilitative GLUT in insulin
sensitive tissues including the heart, skeletal muscle, and
adipose tissue. Quantitative data from this study shows
that GLUT4 mRNA is roughly ten-fold more abundant
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major role in regulating glucose utilization in insulin-
sensitive tissues, genetic ablation of GLUT4 does not re-
sult in overt diabetes but instead GLUT4 null mice exhibit
a range of metabolic abnormalities including marked car-
diac hypertrophy [21]. Even with the absence of the major
glucose transporter, however, GLUT4 null hearts transport
normal levels of glucose and synthesize normal levels of
glycogen [22]. To determine whether other facilitative
GLUTs are upregulated in the absence of GLUT4 in order
to enable GLUT4 null hearts to maintain a high level of
glucose metabolism, we examined the fold change in
GLUT transcripts in RNA isolated from the left ventricles
of six-month-old GLUT4 null males and age matched
controls. As expected, our primers detected a 94% de-
crease in GLUT4 mRNA levels in the left ventricle of the
GLUT4 null mouse. We did not observe a significant
change in the transcript levels of GLUTs-1, -3, -8, or −10
in the left ventricles of GLUT4 null mice compared to
wild type C57BL/6J controls (Figure 2). While GLUT1
levels were elevated in the left ventricles of GLUT4 null
mice, this increase in transcript levels did not reach sig-
nificance (p= 0.05). We did however observe a significant
increase in the transcript levels of GLUT12 in the left ven-
tricles of GLUT4 null mice.GLUT protein expression in GLUT4 null mice
To determine whether changes in GLUT transcript
levels correlate with changes in protein level in the
GLUT4 null myocardium, we used western blotting toFigure 2 Relative expression of GLUT transcripts in the left
ventricle of the murine GLUT4 null model of cardiac hypertrophy.
Comparative real time PCR was performed to examine the relative
mRNA expression of GLUT transcripts in left ventricles derived from
six-month-old GLUT4 null and C57BL/6J mice. Real time PCR
demonstrates an increase in GLUT12 mRNA expression in the left
ventricles of GLUT4 null mice (n= 6 mice/group). *, P< 0.05.examine the protein expression of GLUT1, GLUT4,
GLUT8, and GLUT12 in GLUT4 null mice and in wild
type controls. Our data show that GLUT1, GLUT4, and
GLUT8 are the most abundant GLUT transcripts in the
left ventricle. Furthermore, GLUT12 mRNA levels are
elevated in the left ventricle of GLUT4 null mice com-
pared to wild type controls. As predicted, GLUT4 pro-
tein expression was dramatically diminished in the
GLUT4 null myocardium (Figure 3). Our western blot
data also show that the expression levels of GLUTs-1, -8,
and −12 were significantly elevated in the GLUT4 null
myocardium compared to wild type controls.
GLUT transcript expression in genetic and surgical murine
models of cardiomyopathy
To determine whether the myocardial expression levels
of the more recently identified glucose transporters
modulate in situations of chronic cardiac stress, we mea-
sured the fold change in GLUT transcripts in the left
ventricle of a genetic murine model of dilated cardiomy-
opathy. TG9 mice develop echocardiographic evidence
of left ventricular dilatation and systolic dysfunction by
8 weeks of age followed by a steady increase in chamber
size and decrease of contractile function leading to de-
compensated heart failure and death between 11–13 and
weeks [23]. Eighty-five day old male TG9 mice that were
in advanced stages of heart failure were sacrificed and
the left ventricle was harvested. RNA was isolated from
the left ventricle and cDNA was synthesized as described
above. Real time PCR showed that significant differences
exist between GLUT transcript levels in the left ventri-
cles of TG9 mice compared to age matched controls
(Figure 4). At 70 days of age, which is just prior to the
development of overt cardiac dysfunction [23], GLUT1
and GLUT10 transcript levels were comparable to wild-
type control mice whereas message for the insulin-
responsive GLUTs −4, -8 and −12 were significantly
lower (Figure 4A). By 85 days of age, GLUT1 transcript
levels were significantly elevated in the TG9 ventricles
compared to age-matched wild-type controls (Figure 4B).
GLUT3 transcript levels also increased, but differences
in relative transcript levels between wild-type and TG9
mice did not reach significance (p = 0.08). Relative tran-
script levels of GLUTs −4, -8, and −12 remained lower
in the TG9 left ventricle compared to wild type controls.
To determine whether mRNA expression levels of the
GLUTs similarly varies in a murine model of pathological
hypertrophy induced by cardiac pressure overload,
C57BL/6J male mice were subjected to aortic banding (or
sham) surgeries. One week following surgery, RNA was
isolated from left ventricles of surviving animals. As
expected, the aortic banding surgery induced a significant
degree of hypertrophy in the left ventricles (Figure 5A).
Real time PCR showed that relative transcript levels were
Figure 3 Relative expression of GLUT protein in the left ventricle of GLUT4 null mice. Western blotting was performed to examine the
relative expression of GLUT1 (A), GLUT4 (B), GLUT8 (C), and GLUT12 (D) in the LVs of C57BL/6J and GLUT4 null mice. GLUT1, GLUT8, and GLUT12
protein expression is significantly elevated in the LVs of GLUT4 null mice compared to wild type controls (n = 3-4 mice/group). *, P< 0.05.
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GLUTs −1, -4, -8 and −10 in mice one week following aor-
tic banding (Figure 5B).
Discussion
The uptake and metabolism of glucose significantly con-
tributes to the production of myocardial ATP under nor-
mal conditions. Glucose assumes an even greater role in
energy production in the heart during increased work-
load, ischemia, and pressure overload hypertrophy [1,2].
Because alterations in myocardial glucose utilization
occur under conditions of cardiac injury or stress, better
understanding of the factors that control the transport
of glucose into the myocardium is vitally important for
efforts to improve clinical outcomes in affected patients.
The entry of glucose into the heart is mediated by mem-
bers of the GLUT family of facilitative transporter pro-
teins. While prior research has focused primarily on
understanding the roles of the ubiquitous glucose trans-
porter GLUT1 and the insulin-sensitive glucose trans-
porter GLUT4 in regulating myocardial glucose uptake
[21,22,24-26], less attention has been devoted to eluci-
dating the roles of other GLUT isoforms in both the
normal heart and in pathological states. To this end, we
set out to define and characterize the presence and rela-
tive abundance of GLUT isoforms in the healthy adult
murine left ventricle. Furthermore, we examined how
the expression levels of each of these isoforms change
under pathophysiological conditions.Functional implications of GLUT expression in the healthy
heart
The current data show that mRNA encoding GLUTs-1,
-3, -4, -8, -10, and −12 are present in the left ventricles
of adult male FVB/NJ and C57BL/6J mice, two common
strains of mice used for generating both genetic and sur-
gical models of heart failure and stress. The presence of
these isoforms in the murine left ventricle is in agree-
ment with previous studies detecting these GLUTs in
mammalian hearts [10-13,20,27]. GLUT6 was also
detected in the left ventricles of FVB/NJ mice, which has
not been previously reported. GLUT5 was detectable in
some but not all of the left ventricles derived from adult
male FVB/NJ and C57BL/6J mice. Due to the inability to
subclone a GLUT5 amplicon derived from left ventricu-
lar cDNA into a pCR2.1-TOPO cloning vector to be
used as a template for a standard curve, the presence of
this transporter isoform in left ventricular myocardium
could not be confirmed and relative expression levels
could not be quantified. While trace levels of GLUT5
mRNA may be present in the myocardium, because the
total RNA in this study was isolated from whole tissue
rather than isolated cardiomyocytes, it is possible that
the low level detection of GLUTs 5 and 6 may have been
derived from small amounts of other cell types harvested
along with the left ventricle.
Due to a diversity of detectable GLUTs in the heart,
characterization of the relative abundance of each of
these GLUTs in the heart is an important step towards
Figure 4 Relative expression of GLUT transcripts in the left
ventricle of the TG9 model of dilated cardiomyopathy.
Comparative real time PCR was performed to examine the relative
mRNA expression of GLUT transcripts in left ventricles derived from
A. 70-day-old and B. 85-day-old TG9 mice (TG9) and FVB/NJ controls
(WT). Real time PCR shows that the expression levels of GLUT1
mRNA increase significantly in TG9 mice compared to age matched
controls during heart failure progression. Conversely, the transcript
levels for the insulin responsive glucose transporters GLUT4, GLUT8,
and GLUT12 are significantly lower in heart from TG9 mice
compared to FVB/NJ controls (n = 6–11 mice/group). *, P< 0.05.
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towards maintaining myocardial glucose transport under
healthy settings. Based on their relative transcript abun-
dance in the left ventricles of both FVB/NJ and C57BL/
6J mice, GLUT4, GLUT1, and GLUT8 likely serve im-
portant physiological roles in the healthy heart. The
mRNA levels of GLUT3, GLUT6, GLUT10 and
GLUT12 are comparatively less abundant. This may
point to a more limited role for these isoforms in regu-
lating myocardial glucose uptake under healthy circum-
stances. It is important to note, however, that the
relative abundance of GLUT mRNAs in the LV may not
directly correlate with the relative abundance of GLUT
protein. Clearly, more research is needed to determine
the precise roles that each of these transporters play in
the heart and in other mammalian tissues. It is possible
that several of the expressed GLUT isoforms havesignificant functions in this tissue that are distinct from
their putative roles as glucose transporters.
The relative abundance of GLUT8 mRNA in the left
ventricles of adult FVB/NJ and C57BL/6J mice suggests
that this isoform may play a role in facilitating hexose
transport across the membranes of myocardial cells. The
functional significance of GLUT8-mediated transport in
normal heart physiology is unclear. While GLUT8 has
been reported to act as an insulin-responsive GLUT iso-
form in murine blastocysts [15], in other many mamma-
lian cell types GLUT8 localizes primarily to lysosomal
compartments and does not translocate to the cell surface
in response to insulin. Additionally, unlike the genetic ab-
lation of GLUT4, which results in severe cardiac hyper-
trophy in mice [21], the genetic ablation of GLUT8 does
not influence cardiac size or morphology [28]. The
GLUT8 null heart does however display an increased P-
wave duration in electrocardiogram analysis, suggesting
that this transporter isoform may influence atrial contrac-
tion [28]. Further investigation is warranted to determine
whether GLUT8 directly influences myocardial glucose
utilization or has a separate role in influencing normal
cardiac physiology.
Compensatory changes in myocardial GLUT expression
following GLUT4 ablation
Our data show that GLUT4 mRNA in the left ventricle is
more abundant than mRNA for every other GLUT iso-
form combined. Genetic ablation of GLUT4 in the heart
has been shown to result in pronounced cardiac hyper-
trophy that is similar to hypertrophy that is induced by
hypertension [21]. While the molecular mechanisms lead-
ing to hypertrophy in GLUT4 null mice are likely com-
plex, hyperinsulinemia, hypertension and oxidative stress
have been implicated as contributing factors [29,24]. Inter-
estingly, despite the absence of the most abundant GLUT
isoform in the heart, GLUT4 null mice continue to trans-
port glucose into the heart at normal levels [22]. Previous
studies have suggested that upregulation of the GLUT1
isoform is responsible for maintaining normal levels of
glucose transport into the heart. Our study shows that in
addition to GLUT1, the protein levels of the GLUT8 and
GLUT12 isoforms and the transcript levels of the
GLUT12 isoform are also elevated in the left ventricles of
GLUT4 null mice. The observed discrepancies between
GLUT gene and protein expression, which have been
previously observed with GLUT1 and GLUT4, can be
due to changes in translational regulation and/or pro-
tein stability [30,31].
The compensatory increase in the expression levels of
other GLUT isoforms in the left ventricles of GLUT4 null
mice complicates efforts to isolate the effect of GLUT4
ablation on cardiac function. Because the GLUT4 null
heart transports glucose at normal levels, it can be
Figure 5 Relative expression of GLUT transcripts in the left ventricle of a murine model of cardiac pressure overload. Comparative real
time PCR was performed to analyze the relative mRNA expression of GLUT transcripts in the left ventricles derived from C57BL/6J mice in a
pressure-overload induced cardiac hypertrophy setting. A) An increased left ventricle to body weight ratio shows that mice receiving TAC were
experiencing compensatory cardiac hypertrophy. B) Real time PCR shows that the expression levels of GLUT transcripts were lower in mice
receiving aortic constriction compared to sham operated animals (n = 6-7 mice/group). *, P< 0.05.
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lated in the absence of GLUT4 serve a compensatory role
in facilitating glucose uptake into the heart. These changes
may influence glucose flux directly through increased
levels of transporter protein within the plasma membrane
or indirectly via alterations in cellular signaling pathways
[32]. Similar alterations in GLUT isoform expression may
also contribute to the observed dissociation between
changes in GLUT4 expression and insulin sensitivity in
other models such as exercise detraining [33].
Since the normal functions of the newer members of
the GLUT family remain poorly characterized, it is pos-
sible that elevated GLUT8 and GLUT12 expression con-
tributes to the hypertrophic phenotype observed in
GLUT4 null hearts. The ability to disrupt glucosetransport in an isoform-selective manner would provide a
means to better clarify how each GLUT isoform partici-
pates in normal and pathological cardiac function in the
absence of compensatory changes in GLUT expression.
Our laboratory has previously demonstrated that the HIV
protease inhibitor (PI) indinavir can acutely, selectively,
and reversibly inhibit GLUT4 activity in vitro and in vivo
[34-36]. Ongoing efforts to identify the structural basis for
PI binding to GLUTs will aide in the development of novel
pharmacological agents that specifically inhibit other
GLUT isoforms. This development would enrich our abil-
ity to explore how each GLUT isoform affects energy
homeostasis in specific mammalian tissues.
Previous studies have demonstrated that isolated so-
leus muscle of female GLUT4 null mice displays
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stimulation [37]. This demonstrates that an additional
isoform is able to compensate at least partially for the
genetic ablation of GLUT4 by acting as an insulin-
responsive GLUT. At the time that this observation
was made, several GLUTs including GLUT12 had not
yet been identified. The increased expression of
GLUT12 in GLUT4 null mice provides evidence that
GLUT12 mediates the observed increased glucose up-
take. Recent studies have demonstrated that GLUT12
traffics to the cell surface of skeletal muscle in re-
sponse to insulin-stimulation [38] and that GLUT12
overexpression in mice improves insulin sensitivity
[16]. The increase in GLUT12 mRNA expression in
the GLUT4 null LVs suggests that GLUT12 may be
playing a role as a second insulin responsive GLUT
in the myocardium. It is still unclear whether GLUT12
translocates to the cell surface in response to contractile
stimulation. Because the expression level of GLUT4 is
normally significantly greater than GLUT12, it is unclear
how much GLUT12 contributes to maintaining myocar-
dial glucose homeostasis in the healthy heart.
Changes in myocardial GLUT expression under
pathophysiologic conditions
Although mRNAs for GLUTs-3, -8, -10, and −12 are
present in the LV at comparatively lower levels than
GLUTs-1 and −4, it is possible that these isoforms play a
greater role in regulating myocardial glucose uptake
under pathological circumstances. We therefore exam-
ined the expression levels of each GLUT isoform in TG9
mice in advanced stages of dilated cardiomyopathy, and
in murine surgical model of pressure overload hyper-
trophy. We found that the transcripts for GLUT1 and
GLUT3 increased as heart failure developed in TG9
mice while transcripts for GLUT4, GLUT8, and
GLUT12 were all decreased. The upregulation of both
GLUT1 and GLUT3 in TG9 mice is consistent with
prior reports of altered gene transcription during heart
failure [39]. Both GLUT1 as well as GLUT3 are com-
monly found in high abundance in fetal tissues [40] and
GLUT1 is the major GLUT expressed in the fetal heart
[7]. The relative changes in mRNA transcript levels
observed in the aortic banding model, however, demon-
strate that pathologic cardiac hypertrophy is not neces-
sarily accompanied by an increase in GLUT1 mRNA
expression.
The decreased expression of GLUT12 in both the TG9
and aortic banding model in our study contrasts with a
previous report of increased GLUT12 mRNA levels in a
canine tachypacing heart failure model [20]. It is possible
that this discrepancy reflects differences between species
and specific molecular mechanisms for heart failure.
This underscores the need for caution againstovergeneralization of the findings from unique heart fail-
ure models. Clearly, continued efforts to more exten-
sively identify and characterize the complex cellular
changes that occur during heart failure development will
allow greater insight into the mechanisms and functional
consequences of altered myocardial GLUT expression.
Conclusions
Our data show that at least six members of the facilita-
tive GLUT family are detectable in murine left ventricu-
lar tissue. Significant changes occur in mRNA message
levels in mice with heart disease induced by different
mechanisms. It remains to be determined whether these
changes are adaptive or maladaptive. Continuing efforts
to identify and characterize the functional significance of
each of these isoforms in the myocardium will further
enhance our understanding of myocardial energy dy-
namics under both healthy conditions and pathological
circumstances. This work will serve as a basis for future
efforts to investigate the individual roles of these newly
identified GLUT isoforms in regulating myocardial en-
ergy dynamics.
Additional file
Additional file 1: Figure S1. Detection of GLUT mRNAs in the left
ventricle of FVB/NJ mice. A) PCR was employed to identify each known
murine member of the facilitative glucose transporter family in the left
ventricle of 10-week-old male FVB/NJ mice. GLUTs-1, -3, -4, -6, -8, -10, and
−12 were amplified using cDNA derived from the left ventricular
myocardium. The identity of each GLUT amplicon was confirmed by
sequencing. A faint band for GLUT5 was detected in some but not all of
the left ventricles analyzed. GLUTs-2 and −9 were not present in the left
ventricle of male C57BL/6J mice. Representative images are shown
(n = 3). B) The specificity of the primers used to amplify GLUTs-2 and −9
were confirmed using cDNA derived from liver and intestine, respectively.
The specificity of the primers for each GLUT amplicon was confirmed by
sequencing.
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